Abstract
With the improvement in our understanding of the molecular biology of renal cell carcinoma (RCC), a number of targeted therapeutics have become available for treatment of this disease, both FDA approved and in the experimental realm. The epidermal growth factor receptor (EGFR) family of molecules is an attractive target in RCC due to their overexpression on RCC tissue, and the ready availability of agents that target the pathway. This chapter summarizes the molecular biological information available for EGFR in RCC, preclinical work with blocking agents, and the clinical data on use of EGFR targeting strategies in RCC.
Original language | English (US) |
---|---|
Title of host publication | Renal Cell Carcinoma |
Subtitle of host publication | Molecular Targets and Clinical Applications |
Publisher | Humana Press |
Pages | 287-303 |
Number of pages | 17 |
ISBN (Print) | 9781588297372 |
DOIs | |
State | Published - 2009 |
Keywords
- ErbB
- Renal cell carcinoma
- Resistance
- Signaling
- Targeted therapy
ASJC Scopus subject areas
- General Medicine